ArticleJournal of hepatocellular carcinoma2026
Thrombomodulin Mitigates the Progression of Hepatocellular Carcinoma in Steatotic Liver.
Article in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Metabolic dysfunction associated steatotic liver disease promotes intrahepatic metastasis of liver cancer, although not uniformly. However, the mechanisms underlying steatosis-induced progression of liver cancer are not well understood. Antitumor properties of thrombomodulin (TM) are unknown. We aimed to investigate whether TM contributes to the suppression of hepatocellular carcinoma (HCC) progression in the steatotic livers of mice. Methods: Mice were fed a normal or choline-deficient diet (CDD) for 4 weeks, followed by splenic injection of mouse Hepa1-6 cells. Hepatic tumors were analyzed 3 weeks after the injection. Results: CDD induced hepatic steatosis, which resulted in a hypoxic state and the downregulation of TM in the liver. CDD-induced hepatic steatosis promoted HCC progression and increased serum levels of high motility group box 1 (HMGB-1), which were suppressed by recombinant TM (rTM). However, HCC progression was not promoted in non-steatotic livers. In TM Discussion: These findings suggest that hepatic steatosis has a prometastatic effect through the downregulation of TM. TM has a tumor-suppressive function via the inhibition of HMGB-1 activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.